Share Prices & Company Research

Market News

26 Jan 2021 | 07:49

AstraZeneca gets approval for Symbicort Turbuhaler in China

(Sharecast News) - AstraZeneca said on Tuesday that 'Symbicort Turbuhaler', with budesonide and formoterol, has been approved in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve asthma control in patients with mild asthma aged 12 years and older. The FTSE 100 drugmaking giant said the approval by the National Medical Products Administration (NMPA) was based on positive results from the 'SYGMA 1' and 'SYGMA 2' phase 3 trials, published in the New England Journal of Medicine, which evaluated the efficacy of Symbicort Turbuhaler taken as-needed as an anti-inflammatory reliever compared with standard-of-care therapies in mild asthma.

Standard-of-care included short-acting beta2-agonist (SABA) taken as needed, or regular maintenance controller therapy plus SABA taken as-needed.

AstraZeneca said Symbicort Turbuhaler is the first dual-combination therapy approved in China as an anti-inflammatory reliever to treat mild asthma.

It was already approved in China for patients with moderate-to-severe asthma as an anti-inflammatory reliever plus maintenance therapy, and as maintenance therapy only.

"Everyone with asthma is at risk of an attack, regardless of their age, disease severity, adherence to treatment or level of control," said executive vice-president of biopharmaceuticals research and development Mene Pangalos.

"This approval means people with mild asthma in China can now take Symbicort Turbuhaler as an anti-inflammatory reliever to treat their symptoms and also to reduce the likelihood of an attack by treating the underlying inflammation in their airways.

"This approval builds on Symbicort's established role in treating moderate to severe disease."

At 0827 GMT, shares in AstraZeneca were up 0.66% at 7,949p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.